The spotlight falls on the ProPrime II and MeloScript III enzymes, which are engineered to enhance the speed and sensitivity of PCR and qPCR workflows. These tools come with full freedom-to-operate intellectual property protections, allowing manufacturers to integrate them into clinical pipelines with lower regulatory friction. Beyond molecular tools, Fapon is addressing the clinical demand for neurodegenerative diagnostics by offering a comprehensive array of raw materials tailored for blood-based Alzheimer’s biomarker testing, all produced under ISO 13485 standards.

To support these reagents, the company is running live demonstrations of its Shine i-Series CLIA analyzers, specifically the i1000 and i3000 models. These systems are designed for open-platform compatibility, supporting over 70 in-house assays. This exhibition reinforces Fapon’s "In America, For America" strategy, which centers on maintaining domestic R&D and production infrastructure to ensure supply chain stability for local laboratories. By localizing technical support and manufacturing, the firm aims to provide US-based partners with the consistency required for high-stakes diagnostic development.